RUBICON TECHNOLOGIES INC (RBT)

US78112J2087 - Common Stock

0.1715  -0.01 (-6.28%)

After market: 0.1156 -0.06 (-32.59%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to RBT. RBT was compared to 279 industry peers in the Software industry. RBT may be in some trouble as it scores bad on both profitability and health. RBT is quite expensive at the moment. It does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

RBT had negative earnings in the past year.
RBT had a negative operating cash flow in the past year.
In the past 5 years RBT always reported negative net income.
RBT had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

RBT's Return On Assets of -35.08% is on the low side compared to the rest of the industry. RBT is outperformed by 79.71% of its industry peers.
Industry RankSector Rank
ROA -35.08%
ROE N/A
ROIC N/A
ROA(3y)-27.33%
ROA(5y)-30.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

RBT has a Gross Margin of 7.17%. This is amonst the worse of the industry: RBT underperforms 89.13% of its industry peers.
RBT's Gross Margin has improved in the last couple of years.
RBT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 7.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.91%
GM growth 5YN/A

0

2. Health

2.1 Basic Checks

RBT does not have a ROIC to compare to the WACC, probably because it is not profitable.
RBT has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, RBT has a worse debt to assets ratio.

2.2 Solvency

RBT has an Altman-Z score of -0.58. This is a bad value and indicates that RBT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of RBT (-0.58) is worse than 76.09% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.58
ROIC/WACCN/A
WACC8.1%

2.3 Liquidity

A Current Ratio of 0.69 indicates that RBT may have some problems paying its short term obligations.
With a Current ratio value of 0.69, RBT is not doing good in the industry: 89.13% of the companies in the same industry are doing better.
RBT has a Quick Ratio of 0.69. This is a bad value and indicates that RBT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.69, RBT is not doing good in the industry: 88.77% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.69
Quick Ratio 0.69

4

3. Growth

3.1 Past

The earnings per share for RBT have decreased strongly by -90.09% in the last year.
The Revenue has decreased by -2.45% in the past year.
RBT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.95% yearly.
EPS 1Y (TTM)-90.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.5%
Revenue 1Y (TTM)-2.45%
Revenue growth 3Y8.95%
Revenue growth 5YN/A
Sales Q2Q%-9.96%

3.2 Future

The Earnings Per Share is expected to grow by 30.65% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 10.05% on average over the next years. This is quite good.
EPS Next Y63.16%
EPS Next 2Y30.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.48%
Revenue Next 2Y7.88%
Revenue Next 3Y10.42%
Revenue Next 5Y10.05%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RBT. In the last year negative earnings were reported.
Also next year RBT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as RBT's earnings are expected to grow with 30.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.65%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

RBT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

RUBICON TECHNOLOGIES INC

NYSE:RBT (6/7/2024, 8:04:01 PM)

After market: 0.1156 -0.06 (-32.59%)

0.1715

-0.01 (-6.28%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)05-20 2024-05-20/amc
Earnings (Next)08-06 2024-08-06/amc
Inst Owners0.24%
Inst Owner Change-92.35%
Ins Owners72.64%
Ins Owner Change0%
Market Cap9.58M
Analysts80
Price Target1.58 (821.28%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.42%
Min EPS beat(2)0.99%
Max EPS beat(2)19.85%
EPS beat(4)4
Avg EPS beat(4)26.56%
Min EPS beat(4)0.99%
Max EPS beat(4)53.04%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.95%
Min Revenue beat(2)-11.44%
Max Revenue beat(2)-0.46%
Revenue beat(4)1
Avg Revenue beat(4)-3.74%
Min Revenue beat(4)-11.44%
Max Revenue beat(4)0.6%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-24.39%
PT rev (3m)-24.39%
EPS NQ rev (1m)-14.29%
EPS NQ rev (3m)12.73%
EPS NY rev (1m)-19.23%
EPS NY rev (3m)19.04%
Revenue NQ rev (1m)-8.52%
Revenue NQ rev (3m)-10.28%
Revenue NY rev (1m)-2.64%
Revenue NY rev (3m)-4.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.01
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.48
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS12.17
BVpS-2.56
TBVpS-3.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.08%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 7.17%
FCFM N/A
ROA(3y)-27.33%
ROA(5y)-30.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.91%
GM growth 5YN/A
F-Score3
Asset Turnover3.43
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.76%
Cap/Sales 0.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.69
Quick Ratio 0.69
Altman-Z -0.58
F-Score3
WACC8.1%
ROIC/WACCN/A
Cap/Depr(3y)32.16%
Cap/Depr(5y)28.05%
Cap/Sales(3y)0.34%
Cap/Sales(5y)0.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.5%
EPS Next Y63.16%
EPS Next 2Y30.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.45%
Revenue growth 3Y8.95%
Revenue growth 5YN/A
Sales Q2Q%-9.96%
Revenue Next Year2.48%
Revenue Next 2Y7.88%
Revenue Next 3Y10.42%
Revenue Next 5Y10.05%
EBIT growth 1Y82.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year85.47%
EBIT Next 3Y37.32%
EBIT Next 5Y33.73%
FCF growth 1Y-27.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.5%
OCF growth 3YN/A
OCF growth 5YN/A